ABSTRACT
The results of an observational study of amoxicillin/clavulanic acid (Augmentan) in 191 patients are presented. The average duration of treatment was 15 days (median). Healing or improvement was observed in 76% of the cases. In view of the fact that the condition often has a multifactorial genesis and neural and vascular changes impair healing, this result must be considered a clinical success. Variables with an influence on the efficacy of the treatment were the incidence of manifestation and pathogenesis of the ulcer, renal function, blood pressure and smoking. Amoxicillin/clavulanic acid was well tolerated, with adverse events being observed in only 9 out of 193 patients (4.7%). Treatment was abandoned because of adverse events in 3 out of 193 patients (1.6%). Overall, treatment of the infected diabetic foot with amoxicillin/clavulanic acid was well tolerated and effective.
Subject(s)
Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Diabetic Foot/drug therapy , Adult , Aged , Aged, 80 and over , Amoxicillin-Potassium Clavulanate Combination/adverse effects , Anti-Bacterial Agents/adverse effects , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Treatment OutcomeSubject(s)
Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Bacterial Infections/drug therapy , Diabetic Foot/drug therapy , Drug Therapy, Combination/therapeutic use , Adult , Amoxicillin-Potassium Clavulanate Combination/adverse effects , Dose-Response Relationship, Drug , Drug Therapy, Combination/adverse effects , Female , Humans , Male , Treatment OutcomeABSTRACT
UNLABELLED: The efficacy and safety of N-acetylcysteine prescribed in general practice were investigated. METHOD: open, non-controlled surveillance study conducted at 744 centers. PATIENTS: 3,076 patients suffering from bronchitis. MEDICATION: 600 mg N-acetylcysteine (Fluimucil-Long, Inpharzam Germany), administered as a single daily dose. END POINTS: evaluation of coughing, amount and quality of sputum, expectoration, dyspnea, compliance and tolerance. RESULTS: impressive improvement of the symptom complex, good compliance. Adverse reactions were reported in 45 patients (rate: 1.5%). CONCLUSIONS: treatment of chronic and acute bronchitis with the mucolytic agent N-acetylcysteine administered once daily, proved to be both effective and well tolerated.